Physician profile
Ankush Bansal
NPI 1013913102
$1,817.56
in general payments reported to CMS, 2019-2025
16 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2021: $51.00 · 2022: $209 · 2023: $179 · 2024: $25.25 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $621.50 | 2019 | |
| Stimwave Technologies Incorporated | $330.72 | 2019-2021 | |
| Abbott Laboratories | $195.84 | 2022-2023 | Proclaim |
| Si-Bone, INC. | $144.06 | 2019 | |
| Avanos Medical | $144.00 | 2022 | |
| Bioventus LLC | $70.59 | 2025 | Durolane |
| Boston Scientific Corporation | $70.35 | 2019-2025 | Intracept |
| Zyla Life Sciences, INC. | $41.20 | 2019 | |
| Straumann USA LLC | $37.12 | 2025 | |
| Ziehm-Orthoscan, INC. | $36.32 | 2019 | |
| Eisai INC. | $25.27 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $25.25 | 2024 | Iovera, Zilretta |
| Daiichi Sankyo INC. | $22.86 | 2019 | |
| Redhill Biopharma INC. | $22.48 | 2023 | Aemcolo, Talicia, Movantik |
| Scilex Pharmaceuticals INC. | $16.20 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electronic Waveform Lab, INC. | $13.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankush Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.